|
|
In 1987, a small team of pioneering young researchers launched Cephalon with the vision of building an integrated biopharmaceutical company with a presence in major markets around the world. That vision is being realized, in the lab, in the clinic and the marketplace, as our expanded market presence, international infrastructure and research scope brings important new treatments to patients and physicians.
Today, Cephalon is poised for a new level of growth, with an expanded international presence, a diverse product portfolio, and medications with even greater therapeutic potential. The business is focused on therapeutic areas where our knowledge is deepest: disorders of the central nervous system, pain, cancer and addiction.
From researching target molecules to advancing late-stage compounds, Cephalon is contributing to scientific understanding while preparing a new portfolio of therapies. We apply our insights from years of early investigations of neurodegenerative disease to developing a broad pipeline of new cancer therapies, where our knowledge of cell survival can have profound impact.
|
|